劲方医药
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer 2024-04-19 19:00
GenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting 2024-04-09 19:00
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting 2024-04-09 19:00
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma 2024-03-28 19:00
GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia 2024-01-11 19:00
China's First NDA for a KRAS G12C Inhibitor: NMPA Accepts New Drug Application for GFH925 and Grants GFH925 with Priority Review Designation 2023-11-24 19:00
GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL) 2023-10-10 19:00
2023 ASCO | Multi-center Data for Combination Study of GenFleet's GFH018 (TGF-β R1 inhibitor) with Anti-PD-1 Antibody Demonstrates Significant Potential to Enhance Efficacy of Immune Checkpoint Inhibitors among ICI-naïve Patients 2023-06-06 19:00
GenFleet Therapeutics to Present Phase I Data for GFH312 at 2023 American Society for Clinical Pharmacology & Therapeutics Meeting 2023-03-09 19:00
GenFleet receives EMA approval for phase Ib/II study of GFH925 (KRAS G12C inhibitor) in combination with ERBITUX® (cetuximab) treating patients with advanced NSCLC in first-line setting 2023-03-01 19:00
GenFleet Therapeutics and Merck Enter into Trial Collaboration to Initiate Study Investigating Combination Therapy of GFH925 (KRAS G12C inhibitor) and ERBITUX® (cetuximab) 2022-12-19 19:00
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH) 2022-11-28 19:00
GenFleet Therapeutics to Present Data from Phase I Trial of GFH018 Monotherapy at the 2022 European Society for Medical Oncology Annual Meeting 2022-09-07 19:00
GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor (GFH312) 2022-08-18 19:00
GenFleet Therapeutics Raises $75 Million in Series C Financing Led by Huagai Capital, to Advance Innovative Pipeline Highlighting Cutting-edge Therapies 2021-12-31 19:00
GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research 2021-10-21 08:05
GenFleet and Innovent Starts First-in-human Phase I/II Trial of KRAS G12C Inhibitor 2021-09-30 08:05
1